IL-6 upregulates immunosuppressive cells, inhibits anti-tumor immune cells, or reduces their infiltration, constructing a highly immunosuppressive tumor microenvironment, potentially leading to ESCC progression and treatment resistance. Here, IL6 is linked to neoplasm.